Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines

Journal of Infectious Diseases

Volumn 191, Issue 10, 2005, Pages 1734-1746

  Schwartz, Elissa J ^a   Blower, Sally ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE;

ARTICLE; BIOLOGICAL MODEL; DRUG EFFECT; DRUG MECHANISM; EPIDEMIC; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SEROPREVALENCE; UNITED STATES; VACCINATION; VIRUS TRANSMISSION;

HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; INCIDENCE; MODELS, BIOLOGICAL;

EID: 18544374464     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/429299     Document Type: Article

References (49)

1. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
2. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000; 45:1-8.
3. Wald A, Zeh I, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-50.
4. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997; 99:1092-7.
5. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
6. Dix RD, Pereira E, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun 1981; 34:192-9.
7. Dix RD, Mills J. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD. J Med Virol 1985; 17:9-18.
8. Balachandran N, Bacchetti S, Rawls WE. Protection against lethal challenge of BAEB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 1982; 37:1132-7.
9. Byars NE, Fraser-Smith EB, Pecyk RA, et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 1994; 12:200-9.
10. Wachsman M, Aurelian E, Smith CC, Eipinskas BR, Perkus ME, Paoletti E. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J Infect Dis 1987; 155:1188-97.
11. Langenberg AG, Burke RE, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med 1995; 122:889-98.
12. Corey E, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999; 282:331-40.
13. Stanberry ER, Spruance SE, Cunningham AE, et al. Glycoprotein-D - adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-61.
14. Jones CA, Cunningham AL. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 2004; 11:12-7.
15. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004; 11:437-45.
16. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16:96-113.
17. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000; 30:549-66.
18. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001; 357:1513-8.
19. Judson KA, Lubinski JM, Jiang M, et al. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J Virol 2003; 77:12639-45.
20. Lubinski J, Nagashunmugam T, Friedman HM. Viral interference with antibody and complement. Semin Cell Dev Biol 1998; 9:329-37.
21. Lubinski JM, Wang E, Soulika AM, et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 1998; 72:8257-63.
22. Friedman HM. Immunologic strategies for herpes vaccination. JAMA 2000; 283:746-7.
23. Nagashunmugam T, Lubinski J, Wang L, et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 1998; 72:5351-9.
24. Lin X, Lubinski JM, Friedman HM. Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 2004; 78:2562-71.
25. Blower S, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Rev 2003; 5:11-25.
26. Blower SM, Koelle K, Mills J. Health policy modeling: epidemic control, HIV vaccines and risky behavior. In: Kaplan E, Brookmeyer R, eds. Quantitative evaluation of HIV prevention programs. New Haven, CT: Yale University Press, 2002:260-89.
27. Ziv E, Daley CL, Blower SM. Potential public health impact of tuberculosis vaccines. Emerg Infect Dis 2004; 10:1529-35.
28. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B Biol Sci 1993; 253:9-13.
29. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994; 265:1451-4.
30. Blower SM, Koelle DM, Kirschner DE, Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci USA 2001; 98:3618-23.
31. Blower SM, Porco TC, Darby GH. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998; 4:673-8.
32. Gershengorn HB, Blower SM. The impact of antivirals and the emergence of drug resistance: HSV-2 epidemic control. AIDS Patient Care STDS 2000; 14:133-42.
33. Gershengorn HB, Darby GH, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions. BMC Infect Dis 2003; 3:1.
34. Blower SM, Wald A, Gershengorn HB, Wang F, Corey L. Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J Infect Dis 2004; 190:1610-7.
35. Blower SM, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis 2004; 39(Suppl 5):S240-7.
36. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis 1990;69(Suppl):19-36.
37. Oberle MW, Rosero-Bixby L, Lee FK, Sanchez-Braverman M, Nahmias AJ, Guinan ME. Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. Am J Trop Med Hyg 1989; 41:224-9.
38. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994; 2:229-43.
39. Mertz GJ, Benedetti J, Ashley R, Selke S, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
40. Mertz GJ, Coombs RW, Ashley R, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis 1988; 157:1169-77.
41. Benedetti J, Corey L, Ashley R. Recurrence rates of genital herpes after acquisition of symptomatic first episode infection. Ann Intern Med 1994; 121:847-54.
42. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-5.
43. Plotkin S, Mortimer E. Vaccines. 2nd ed. Philadelphia, PA: WB Saunders, 1994.
44. Armstrong GL, Schillinger J, Markowitz L, et al. Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001; 153:912-20.
45. Garnett GP, DubinG, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 2004; 80:24-9.
46. Renzi C, Douglas JM Jr, Foster M, et al. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J Infect Dis 2003; 187:19-25.
47. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1513-21.
48. Wald A, Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis 2003; 187:1509-12.
49. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:1009-16.